Analyst (for Kelly Shi)'s questions to Kymera Therapeutics Inc (KYMR) leadership • Q1 2024
Question
An analyst on behalf of Kelly Shi asked for more detail on the dose level being used in the single-arm Phase 1b trial of KT-621, how it compares to the dose in healthy volunteers, and how it might inform the Phase 2b dose.
Answer
President and CEO Nello Mainolfi declined to comment on the specific dose. He reiterated that the company's goal is to achieve a target degradation profile of over 90% in both blood and skin, and this is the profile they aim to explore in patients. He indicated more details on the dose would be provided alongside future data disclosures.